Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in adrenal cortex cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 41 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 11072
Sealed predictions
- RALYL in dopamine neurons, braak+0.46 (p 0.212) → +0.28 (p 0.461)receipt 11081
Swarm cases
receipt 11081: RALYL in dopamine neurons, braak
- power
- full sample +0.42 (p 0.080, n 18), 95% CI -0.05 to +0.74. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.42 (p 0.086, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.130, n 18). could be the mix.
- skeptic
- leave-one-out range +0.34 to +0.60, sign flips 0; without severely affected donors +0.42 (p 0.080, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RALYL in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts